Kate Haviland

CIK: 0001663022

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)9 (47.4%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)8 (42.1%)

Compensation grants

Other (G, F, J, C, D, …)2 (10.5%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

FULC

Fulcrum Therapeutics, Inc.

Director

BCAX

Bicara Therapeutics Inc.

Director

AVLN

Avalyn Pharma Inc.

Director

BPMC

Blueprint Medicines Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (19 total)

FULC
Fulcrum Therapeutics, Inc.
Jun 30, 2026
Award(A)
Stock Option (right to buy)
Direct
32K shares-
BCAX
Bicara Therapeutics Inc.
Jun 9, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19.5K shares-
AVLN
Avalyn Pharma Inc.
Apr 29, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27K shares-
BPMC
Blueprint Medicines Corp
Jul 17, 2025
Award(A)
Direct
129.2K shares-
BPMC
Blueprint Medicines Corp
Jul 17, 2025
Disposition(D)
Direct
224.4K shares-
BPMC
Blueprint Medicines Corp
Jul 17, 2025
Tender Offer(U)
Direct
70.7K shares-
FULC
Fulcrum Therapeutics, Inc.
Jun 26, 2025
Award(A)
Stock Option (right to buy)
Direct
36K shares-
BCAX
Bicara Therapeutics Inc.
Jun 9, 2025
Award(A)
Stock Option (Right to Buy)
Direct
23.7K shares-
BPMC
Blueprint Medicines Corp
Apr 1, 2025
Sale(S)
Direct
1.2K shares at avg. $87.34$105K
BPMC
Blueprint Medicines Corp
Apr 1, 2025
Sale(S)
Direct
600 shares at avg. $85.47$51K
BPMC
Blueprint Medicines Corp
Apr 1, 2025
Sale(S)
Direct
598 shares at avg. $86.14$52K
BPMC
Blueprint Medicines Corp
Apr 1, 2025
Sale(S)
Direct
100 shares at avg. $88.59$9K
BPMC
Blueprint Medicines Corp
Mar 5, 2025
Sale(S)
Direct
16.2K shares at avg. $88.80$1.4M
BPMC
Blueprint Medicines Corp
Mar 1, 2025
Award(A)
Direct
35.2K shares-
BPMC
Blueprint Medicines Corp
Jan 21, 2025
Sale(S)
Direct
1.4K shares at avg. $110.24$159K
BPMC
Blueprint Medicines Corp
Nov 29, 2024
Sale(S)
Direct
400 shares at avg. $95.40$38K
BPMC
Blueprint Medicines Corp
Nov 29, 2024
Sale(S)
Direct
1.7K shares at avg. $96.74$169K
BPMC
Blueprint Medicines Corp
Nov 29, 2024
Sale(S)
Direct
207 shares at avg. $97.76$20K
BCAX
Bicara Therapeutics Inc.
Sep 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
23.7K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	32,000	-	-	Direct
Jun 9, 2026	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	19,475	-	-	Direct
Apr 29, 2026	AVLN Avalyn Pharma Inc.	Award(A) Stock Option (Right to Buy)	26,978	-	-	Direct
Jul 17, 2025	BPMC Blueprint Medicines Corp	Award(A)	129,210	-	-	Direct
Jul 17, 2025	BPMC Blueprint Medicines Corp	Disposition(D)	224,410	-	-	Direct
Jul 17, 2025	BPMC Blueprint Medicines Corp	Tender Offer(U)	70,729	-	-	Direct
Jun 26, 2025	FULC Fulcrum Therapeutics, Inc.	Award(A) Stock Option (right to buy)	36,000	-	-	Direct
Jun 9, 2025	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	23,746	-	-	Direct
Apr 1, 2025	BPMC Blueprint Medicines Corp	Sale(S)	1,200	$87.34	$104,808	Direct
Apr 1, 2025	BPMC Blueprint Medicines Corp	Sale(S)	600	$85.47	$51,282	Direct
Apr 1, 2025	BPMC Blueprint Medicines Corp	Sale(S)	598	$86.14	$51,512	Direct
Apr 1, 2025	BPMC Blueprint Medicines Corp	Sale(S)	100	$88.59	$8,859	Direct
Mar 5, 2025	BPMC Blueprint Medicines Corp	Sale(S)	16,151	$88.80	$1,434,209	Direct
Mar 1, 2025	BPMC Blueprint Medicines Corp	Award(A)	35,200	-	-	Direct
Jan 21, 2025	BPMC Blueprint Medicines Corp	Sale(S)	1,446	$110.24	$159,407	Direct
Nov 29, 2024	BPMC Blueprint Medicines Corp	Sale(S)	400	$95.40	$38,160	Direct
Nov 29, 2024	BPMC Blueprint Medicines Corp	Sale(S)	1,746	$96.74	$168,908	Direct
Nov 29, 2024	BPMC Blueprint Medicines Corp	Sale(S)	207	$97.76	$20,236	Direct
Sep 12, 2024	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	23,746	-	-	Direct

1-19 of 19 transactions

About Haviland Kate

Haviland Kate (SEC CIK 0001663022) files insider reports with the SEC as Director of Fulcrum Therapeutics, Inc. (FULC), Director of Bicara Therapeutics Inc. (BCAX) and Director of Avalyn Pharma Inc. (AVLN). Signal8 also holds filings tied to 1 other company.

Signal8 holds 14 ownership filings by Haviland Kate (2 Form 3, 12 Form 4), filed between Sep 12, 2024 and Jul 2, 2026. Those filings report 19 transactions, from Sep 12, 2024 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Haviland Kate's filings is in CAMBRIDGE, MA.

Recent filings by Haviland Kate

Jun 30, 2026: Grant or award of FULC derivative securities (Form 4, code A).
Jun 9, 2026: Grant or award of BCAX derivative securities (Form 4, code A).
Apr 29, 2026: Grant or award of AVLN derivative securities (Form 4, code A).
Jul 17, 2025: Grant or award of BPMC shares (Form 4, code A).
Jul 17, 2025: Disposition to issuer transaction of BPMC shares (Form 4, code D).

Other insiders filing for Fulcrum Therapeutics, Inc. (FULC)

TANG KEVIN, 10% Owner
Banks Sonja, Director
Dorton Katina, Director
Gould Robert J, Director
King Rachel K., Director
GERAGHTY JAMES A, Director

How to read Form 4 transaction codes